Advanced research on deep brain stimulation in treating mental disorders (Review)

DONGXIN WANG1, XUEJUN LIU1, BIN ZHOU2, WEIPING KUANG2 and TIANSHENG GUO1*

1Mental Health Institute of Hunan Province; 2Surgery Department of Mental Disease, The Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China

Received September 9, 2015; Accepted July 10, 2017

DOI: 10.3892/etm.2017.5366

Abstract. Deep brain stimulation is a method that involves using an electric stimulus on a specific target in the brain with stereotaxis. It is a minimally invasive, safe, adjustable and reversible nerve involvement technology. At present, this technique is widely applied to treat movement disorders and has produced promising effects on mental symptoms, including combined anxiety and depression. Deep brain stimulation has therefore been employed as a novel treatment for depression, obsessive-compulsive disorder, habituation, Tourette’s syndrome, presenile dementia, anorexia nervosa and other refractory mental illnesses. Many encouraging results have been reported. The aim of the present review was to briefly describe the mechanisms, target selection, side effects, ethical arguments and risks associated with deep brain stimulation. Although deep brain stimulation is a developing and promising treatment, a large amount of research is still required to determine its curative effect, and the selection of patients and targets must be subjected to strict ethical standards.

1. Introduction

Electric shock treatment (EST) is a psychotherapy that may be used alone or in combination with drug therapy, and has demonstrated positive curative effects in the treatment of mental disorders (1,2). However, there are a considerable number of patients, known as ‘refractory’ patients, who are immune to these clinical interventions and show little possibility of recovery (3). Refractory mental illnesses contribute greatly to disability worldwide; therefore identifying effective alternative therapies may make a huge difference for such patients.

Deep brain stimulation (DBS) is accomplished via a nerve stimulator implanted in the body and supplied by a battery source, commonly known as a brain pacemaker (4). Typically, a pulse generator supplied with a lithium battery is placed under the skin in the chest area, with one or two wires attaching it to an implanted electrode that is oriented to the target region for brain stimulation (inserted using the stereotactic technique) (5). The pulse stimulation is conducted from the generator to the electrode in the location of interest in the deep brain (Fig. 1) (6). DBS has been used as a treatment for mental diseases since 1987 (7). DBS as a treatment for chronic diseases was first employed by Benabid et al to treat dyskinesia (7) and at present, is primarily used to treat tremors caused by Parkinson’s disease, chronic pain and dysmyotonia. Attempts have been made to develop its use in the treatment of mental disorders (8).

The first mention of using DBS to treat mental diseases in literature was in a report published in the Lancet journal in 2002 discussing the therapy as a possible treatment for obsessive-compulsive disorder (OCD) and transient tic disorder (8). The first report suggesting that DBS could treat depressive disorder was published in 2005 (9). DBS has been authorized for the treatment of epilepsy and OCD in Europe, and for the treatment of refractory OCD treatment in the USA (10). This approval has increased research and promoted the development of DBS, particularly regarding the mechanisms of vagus nerve stimulation (11).

Side effects are uncommon following treatment with DBS, and only mild side effects have been observed when it is used as a treatment for dyskinesia (12). This highlights the advantages of DBS technology; it has good specificity, and the inhibitory effect of deep brain stimulation on the motor nucleus of the thalamus disappeared after the cessation of stimulation (13).
Such advantages are particularly important considering that at present, there are no effective therapies available to treat the majority of mentally handicapped individuals. To treat conditions where it is unknown whether the therapy will have beneficial effects, the moral compulsory principle of ‘no harm’ makes DBS an attractive option. Unlike neurosurgical treatments, DBS is fully reversible, providing the potential means to identify therapeutic targets for the treatment of mentally handicapped individuals without risking permanent damage (Fig. 2) (14).

The current review summarizes the selection and relative benefits of different therapeutic targets of DBS therapy, including refractory depression, OCD, habituation, Tourette’s syndrome (TS), anorexia nervosa (AN) and Alzheimer’s disease.

2. Mechanisms of DBS

The neurobiological mechanisms by which DBS regulates brain function are not yet fully understood (15). The effect of DBS on the cerebral nuclei target region is either excitatory or inhibitory, depending on the properties of internuncial neurons and the afferent neurons in the target region (16). It has been proposed that high-frequency DBS may induce functional damage to areas surrounding the lesion, including closure of current-dependent ion channels (17) and blocking of depolarization via exhaustion of the neurotransmitter (18). The mechanism by which this damage occurs is synapse inhibition and it is also known as neural activation in the stimulated region (19,20).

Many scholars conclude that the influence of DBS on the neurological network is more complicated than simply damaged surgery and that DBS therapy may affect the neuronal somas and the two-way activation function of axons (21,22). Previous studies have reported that various neurotransmitters, including glutamic acid and dopamine, are released following DBS (23,24). Functional neuroimaging data also indicate that DBS alters the brain activity beyond the target area to a large extent, suggesting that DBS may have a sophisticated neural network control function (9,25–27). Benabid et al (7) suggested that DBS therapy may exert synthetic action involving a variety of mechanisms.

3. The selection of different targets for DBS in treating mental diseases

The foundation of DBS research involves searching for the target region by theoretical derivation (28). The target chosen by theoretical derivation in mental disease therapy is derived from clinical experience, results from brain imaging and the pathophysiological knowledge of various diseases (29). Mental diseases typically do not result from simple pathological changes in a single brain structure, it is thought that certain brain structures may serve different roles in the progression of disease and its relative symptoms. Targets with similar anatomical structures or functional relationships (neural networks) may generate a superposition effect; therefore, different targets may be able to regulate the same pathological network on different nodes (30). It has been determined that the targets discussed below are able to remit psychosis symptoms (Fig. 3) (6).

Depression targets. DBS technology has been used to stimulate Brodmann region cg25 under the cingulate cortex, which serves a pivotal role in regulating negative emotions (9). It has been demonstrated that stimulating this region may have an antidepressant effect (9). Lozano et al (31) demonstrated that it had 55% efficacy, with a follow-up record of 20 patients who underwent the surgery 3–6 years prior. In another group of patients with depression, the anterior limb of the internal capsule was regarded as the target of DBS therapy (32). One month post-surgery, the depressive symptoms of patients remitted were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) (33). This result remained stable as indicated by the rates (53% after 12 months and 71% at last follow-up which ranged from 14 to 67 months). The response criterion indicated a minimum of 50% reduction in MADRS in this study; however, some patients experienced motor fluctuations for >6 months (30).

The nucleus accumbens septi (NAcc) is the DBS treatment target for depression and is able to effectively improve the core symptom of depression, (loss of interest in daily activities), due to the effects of the NAcc on the reward system (14). Bewernick et al (32) followed up 11 NAcc-DBS patients for 4 years and 5 patients (45%) experienced lasting beneficial effects.

The ventral capsula interna/ventral striatum (VC/VS) are also regarded as targets for the treatment of depression and may be associated with the regulation of the reward system neural network (34). Malone et al (35) reported that 15 patients with chronic, serious, refractory depression were treated with DBS on the VC/VS and that 40% of these patients reported positive curative effects 6 months post-surgery.

Other potential functional targets of depression were identified on the basis of animal models and neuroimaging research. Sartorius and Henn (36) first proposed the habenula as a target of DBS in the treatment of depression. This region controls the serotonin-activating nerve fibers dominating the nucleus raphes dorsalis and noradrenergic nerve governing the nucleus ceruleus (37). Sartorius and Henn (36) infer that...
excessive activation of the habenula nucleus is associated with depression, and the lower part of the thalamus neck connects the non-specific thalamic system and the orbitofrontal cortex. The dysfunction of the non-specific thalamic system appears to serve an important role in the development of depression (36). Stimulating the lower part of the bilateral thalamus neck may also remit depression Hamilton Depression Rating Scale (38) grade decreases from 42 to 10 and the positive curative effect is maintained for up to 24 months (36). The use of the blinding method (39) to interrupt the stimulus results in a deterioration of the patient's condition. These targets of depression have only been discussed in case reports so far and require further validation in clinical trials.

Overall, DBS targets for the treatment of depression are being developed continuously. The most effective targets are yet to be identified due to the relatively small sample size that exists at present. However, studies have identified a number of DBS targets that have a persistent anti-depressive effect including the epiphysis frenum, NAcc and the VC/VS (Table I) (9,32,34-36,39,40).

**Targets of DBS for OCD.** OCD has various targets, as the orbital frontal cortex and anterior cingulate cortex are both part of the OCD circuit. Unfortunately, these regions are very large; thus the size of cortex region that needs to be modulated would be too large (39,41). The majority of studies suggested that unilateral or bilateral stimulation of the anterior limb of the internal capsule as the target, and these studies have reported promising results, from partial amelioration to complete remission (42-47). In terms of side effects, several researchers identified that hypomania, which may occur with direct stimulation, disappeared completely following a decrease in stimulation strength (41,45,46). The acies thalamus optic-zona incerta has also been investigated in three patients with Parkinson's disease and OCD, and the corresponding reports indicate an improvement in obsessive-compulsive symptoms (8,48). One patient with OCD and comorbid depression entered remission following DBS treatment targeting the NAcc and the caudate nucleus (8,49). A total of 14 electrode-implanted patients reported highly therapeutic effects following unilateral stimulation of the NAcc.
Table I. Targets of deep brain stimulation in the treatment of depression.

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>Targets</th>
<th>Hypothesis</th>
<th>Hypothesis basis</th>
<th>Maximum sample number (n)</th>
<th>Effectiveness evaluation</th>
<th>(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayberg et al, 2005; Connolly and Thase, 2011</td>
<td>Gyrus Cinguli (Brodmann region Cg25)</td>
<td>Anabiosis of inactivating Cg25</td>
<td>Neuroimaging discovery</td>
<td>20</td>
<td>Persistent effectiveness in 55% subjects over 3-6 years follow-up</td>
<td>(9,40)</td>
</tr>
<tr>
<td>Malone et al, 2009</td>
<td>Anterior limb of internal capsule</td>
<td>Inactivation of abnormal neural network connections</td>
<td>Clinically effective intervening measure of OCD and depression</td>
<td>15</td>
<td>40-45% effective rate</td>
<td>(35)</td>
</tr>
<tr>
<td>Bewernick et al, 2012</td>
<td>NAcc</td>
<td>Regulates a central reward system enhancing the pleasure response</td>
<td>Clinical experience in neurobiology of the reward system</td>
<td>11</td>
<td>Persistent effectiveness in 45% subjects over 4-year follow-up</td>
<td>(32)</td>
</tr>
<tr>
<td>Greenberg, et al, 2010</td>
<td>VC/VS</td>
<td>Regulates and improves the mood and increases motivation</td>
<td>Clinical experience in neurobiology of the reward system</td>
<td>15</td>
<td>Valid in the sixth month in 40% of subjects</td>
<td>(34)</td>
</tr>
<tr>
<td>Sartorius and Henn, 2007</td>
<td>Epiphysis frenum</td>
<td>Inhibition of lateral habenula activating the serotonin and noradrenaline-dopamine system, reducing the HPA axis</td>
<td>Neuroimaging discovery of function in animal research</td>
<td>1</td>
<td>N/A</td>
<td>(36)</td>
</tr>
<tr>
<td>Jiménez et al, 2005</td>
<td>Thalamus</td>
<td>Dysfunction of depression thalamus system and orbital frontal cortex</td>
<td>Neuroimaging discovery of function in animal research</td>
<td>1</td>
<td>N/A</td>
<td>(39)</td>
</tr>
</tbody>
</table>

DBS, deep brain stimulation; NAcc, nucleus accumbens; VC/VS, ventral capsula interna/ventral striatum; HPA, hypothalamic-pituitary-adrenal; OCD, obsessive-compulsive disorder; N/A, not applicable.
Table II. Targets of DBS in the treatment of OCD.

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>Targets</th>
<th>Hypothesis</th>
<th>Hypothesis basis</th>
<th>Maximum sample number (n)</th>
<th>Effectiveness evaluation</th>
<th>Effectiveness evaluation (Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goodman VC/anterior limb of the internal capsule et al, 2010</td>
<td>Transfer between the imaging research of the anterior 6 limb of the internal capsule cortex and the thalamus of patients</td>
<td>Acute reason in 60% of patients at 3-36 month follow-ups</td>
<td>Imaging research</td>
<td>6</td>
<td>Effective in 66% of patients</td>
<td>(51)</td>
</tr>
<tr>
<td>Greenberg VC/VS, 2010</td>
<td>Interrupt or regulate neural network access</td>
<td>Effective in 50% of patients</td>
<td>Imaging research</td>
<td>26</td>
<td>Effective in 50% of patients</td>
<td>(34)</td>
</tr>
<tr>
<td>Aouizerate Caudate nucleus et al, 2004</td>
<td>Direct and indirect regulation Amputation of caudate nuclei of OCD pathways</td>
<td>1 Delayed remission of OCD</td>
<td>Imaging research and volume research</td>
<td>16</td>
<td>Effective in 25-75% of patients at 3 month follow-up</td>
<td>(49)</td>
</tr>
<tr>
<td>Mallet Subthalamic nucleus et al, 2008</td>
<td>Direct and indirect regulation Amputation of subthalamic nuclei and limbic areas of OCD pathways</td>
<td>Imaging research</td>
<td>Imaging research</td>
<td>16</td>
<td>Effective in one side with low efficiency</td>
<td>(52)</td>
</tr>
<tr>
<td>Denys NAcc et al, 2010</td>
<td>Direct pathway activity causes the symptoms of OCD</td>
<td>imaging and volume research</td>
<td>Imaging research</td>
<td>16</td>
<td>Effective in one side with low efficiency</td>
<td>(50)</td>
</tr>
</tbody>
</table>

NAcc, nucleus accumbens; VC/VS, ventral capsula interna/ventral striatum; OCD, obsessive-compulsive disorder.

and VC/VS stimulation improved the condition of 50% of patients (41). Side effects, including transient hypomania and anxiety induced by DBS treatment, are typically eliminated by changing the parameters, including stimulus frequency, pulse widths, stimulus duration and voltage (Table II) (34,49-52).

Various targets of DBS for the treatment of OCD have been verified with encouraging results; however identifying a universal satisfactory target is not yet possible due to small sample sizes. Furthermore, OCD is a heterogeneous disease and patients with different symptom groups may have different ideal targets.

**Targets of DBS habituation.** The application of DBS to treat habituation was reported in a previous case report (15). Studies involving animal models and imaging research are able to further increase understanding regarding the mechanisms and safety of the treatment. Previous studies have reported that there may be a specific ideal target of DBS treatment for habituation (Table III) (53-57). However, it should be noted that the potential targets are not mutually independent and selection of the ideal target requires more support from clinical and research data due to potentially overlapping mechanisms and functions. It is worth noting that the NAcc may be identified as the ideal target for DBS treatment in patients with refractory habituation. A total of 5 clinical studies involving 18 patients have already identified curative effects with no reported side effects (24,57-60). A meta-analysis indicated that the success rate of DBS in the treatment of drug addiction is up to 49% (61).

**Targets of TS.** TS is a neuropsychological disease characterized by phonation spasm and motion spasm, with a 1% prevalence rate (62). TS is linked to a number of psychiatric disorders, including obsessive-compulsive disorder (63), and some patients with TS may present with symptoms of disability (64,65). Standard medical treatment for TS does exist, including drug therapy and behavioral intervention (66). Even with the best psychotropic drug treatment and psychological behavioral therapy, only 1/3 of patients receive complete relief; however, 30-40% of patients experience exacerbations and ~5% of patients develop disabilities (66,67). Therefore, it is necessary to explore new therapies, including surgery, for patients whose condition is difficult to control. Researchers have previously attempted to perform nerve surgical resection in patients with TS with mixed success; the central tract complexus region in the thalamus was found to be the most effective target after different targets were attempted (68). Based on results for OCD and dyskinesia treatment, researchers have speculated that the internal segment of globus pallidus (GPI) and the VC/VS as DBS targets may also be effective at treating refractory TS (69).

The targeting of the thalamus DBS to treat TS has been suggested (70). An open-label study of 18 patients preliminarily reported positive results at 3- and 18-month follow-ups, and a 2-year evaluation indicated that the severity of spasms, obsessive-compulsive symptoms, anxiety and depression had decreased remarkably (62,71). A case report also declared that DBS of the GPI and VC/VS may have potential curative effects in patients with severe TS (66). In 1999, Vandewalle et al (72) reported the case of a 42-year-old patient with intractable TS whose twitch symptom was eliminated 1 year following
Table III. Targets of DBS in the treatment of habituation.

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>Targets</th>
<th>Hypothesis</th>
<th>Hypothesis basis</th>
<th>Maximum sample number (n)</th>
<th>Effectiveness evaluation</th>
<th>(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levy et al., 2007</td>
<td>ACC</td>
<td>Participate in the reward system function</td>
<td>Neuroimaging findings, animal experiment</td>
<td>1</td>
<td>Efficient in animal experiment</td>
<td>(55)</td>
</tr>
<tr>
<td>Müller et al., 2009</td>
<td>NAcc</td>
<td>The regulation of NAcc, blocking the selective preference location of morphine</td>
<td>Clinical experience of reward systems neurobiology</td>
<td>3</td>
<td>2 patients with good curative effect, 1 patient remitted</td>
<td>(57)</td>
</tr>
<tr>
<td>Friedman et al., 2010</td>
<td>Epiphysis</td>
<td>Inhibition of lateral habenula inducing the raising of serotonin activation and noradrenaline-dopamine system, reducing of HPA axle</td>
<td>Neuroimaging findings, animal experiment</td>
<td>1</td>
<td>Efficient in animal experiment</td>
<td>(54)</td>
</tr>
<tr>
<td>Forget, et al., 2010</td>
<td>Insular cortex</td>
<td>Inhibiting the gyrus regulation and affecting the practical enteroceptive which participates in the coding habituation</td>
<td>Neuroimaging findings, animal experiment</td>
<td>1</td>
<td>Efficient in animal experiment</td>
<td>(53)</td>
</tr>
<tr>
<td>Lim et al., 2009</td>
<td>Subthalamic nucleus</td>
<td>Key position of the habituation</td>
<td>Regulating function of dopamine</td>
<td>19</td>
<td>Part of patients improved while majority invalid even exacerbation</td>
<td>(56)</td>
</tr>
<tr>
<td>Friedman et al., 2010</td>
<td>LHB</td>
<td>Control reward pathway of the midbrain and further effect the activation of NAcc</td>
<td>Regulating the dopamine neurons</td>
<td>1</td>
<td>Efficient in animal experiment</td>
<td>(54)</td>
</tr>
</tbody>
</table>

DBS, deep brain stimulation; ACC, Anterior cingulate cortex; LHB, Lateral habenular nucleus; HPA, hypothalamic-pituitary-adrenal; NAcc, nucleus accumbens.
implantation of a double-sided electrode in the thalamic nuclei. In the 1960s, Hassler and Dieckmann (73) damaged the thalamic nuclei in 3 TS subjects; since then, considerable research has been conducted on the effectiveness of DBS treatment by implanting electrodes in the thalamic nuclei or other targets, such as the globus pallidus. These studies have reported significant improvements in twitch scores, although a proportion of patients experienced a variety of side effects, including energy loss, fatigue, lazy speech, less movement and decreasing libido (38,74). However, the maximum sample size investigated thus far contained only 18 subjects and few randomized double-blind trials have been conducted (62,75). The present evidence, however, is enough to support large-scale randomized clinical trials of DBS treatment for TS, with an aim to clarify the mechanism.

Targets of Alzheimer's disease (AD). AD is a neurodegenerative disease with a prevalence of 1-2% in America (76). More than 10% of people >65 years old have AD and the primary therapies available at present are drugs that slow down rather than prevent further cognitive decline (77). One case report described hyperamnesia in a patient with obesity treated with fornix DBS (76). Based on this report, Laxton et al (78) published a first phase clinical trial involving 6 elderly patients with AD who underwent DBS of the fornix. At a 1-year follow up, the glycometabolism in the parietal lobe brain had improved markedly. The potential mechanisms of this method are not yet clear; however, it is thought that activation of the fornix axon in turn activates the downstream brain regions involved in memory. In 2 patients who were examined using the simple mental symptoms scale (78), the speed of memory decline was demonstrated to have slowed down and a clinical improvement in symptoms was observed win no evident side effects. The effectiveness of this method of treatment for AD further supports the use of electric stimulation therapy as a treatment for neurodegenerative diseases including Parkinson's, AD, myodystonia, OCD, TS and depression.

Targets of AN. AN is an eating disorder that individuals experience to different extents, from being on a diet and deliberately inducing weight loss to deliberately and dramatically reducing body weight to far below healthy levels (79). The primary symptoms of AN are an excessive attention to weight and body image, intense fear of gaining weight, obsessive pursuit of thinness and significant reduction in weight. This is often combined with malnutrition, as well as metabolic and endocrine disorders, such as amenorrhea (80). AN can be a life-threatening condition due to excessive malnutrition, leading to cachexia and body failure. Morbidity rate of AN is between 5-15%, with patients typically succumbing to cardiac complications, multiple organ failure, secondary infection or suicide (81-86).

Research into the targets of DBS to treat AN is in the animal experiment stage at present, and the primary experimental targets include the anterior hypothalamic nucleus (AHN) and NAcc (87).

Research involving low frequency electric excitement and electrolytic damage in canine and feline models identified that the AHN controls eating behavior and the metabolism of food in the body (88). A previous study has reported that the ventromedial hypothalamic nucleus (VMH) and lateral hypothalamic nucleus have an adverse function by which they can present opposite effects with electrical excitation or depolarization. Damage to the VMH induces overfeeding and obesity, whereas low frequency electrical stimulation results in reduced food intake (87). It is thought that countering this action with high frequency electrical stimulation may increase food intake to remedy AN; however, the present research is only limited to animals (87).

Experimental data has also suggested that high-frequency DBS in the NAcc region may be an effective treatment for AN, OCD, depression and drug dependence (87). However, there are no related clinical experimental results at present (87).

4. The side-effect of DBS

Approximately 80,000 individuals have undergone DBS treatment worldwide, with a reported mortality rate of 0-0.4% (10). The side effects associated with DBS are categorized as acute side effects of surgery and long-term side effects.

Acute side effects of surgery. The acute side effects of surgery observed in large sample research studies include physical and mental side effects. Physical side effects include intracranial hemorrhage, which has a prevalence of 0.4-1.3% and irreversible brain damage, which has a prevalence of 0.8% (89). Furthermore, studies in patients who have undergone DBS have found that the prevalence of infection, epileptic seizure and cutaneous complications are 0.7, 1.5 and 25%, respectively (87,90,91).

One of the most harmful side effects of DBS is the risk of inducing psychiatric symptoms that differ from the therapy. Mental complications include transient aggressiveness, hypomania, mania, depression, anxiety, apathy and even suicide. The most common side effect is postoperative delirium (15.6%), followed by depression and hypomania (92). For DBS treatment of Parkinson's disease, for example, the most severe side effect is an increased suicide risk, particularly when the target region is in the subthalamic nucleus and globus pallidus internus (87), with large sample research reporting a suicide risk of 0.16-0.32%. It is therefore necessary to highlight the suicide risk screening of patients undergoing DBS.

Long-term side effects of surgery. A previous study has reported no serious side effects or pathological damage to other brain parenchymal tissue associated with the permanent implant, apart from cerebellar mass cell hyperplasia surrounding the electrode observed in the dissection results (93). Overall, an adverse outcome may result from a combination of mental, societal and operational factors (94). Issues with cognition have also been reported, most notably deficiencies of language fluency (95). It should be noted that there is currently no large-scale randomized blinded study data able to determine the long-term impacts of DBS on personality, cognitive function, attention and self-awareness. Overall, the side effects of DBS are much less prevalent and less serious than those of stereotactic surgery and there are fewer post-surgical complications associated with DBS. Furthermore, electrodes can be blocked to cease treatment if severe side effects manifest, to prevent further damage occurring.
5. Discussion

DBS has some advantages compared with destructive and disruptive surgical techniques; however, the treatment process is slow and still requires invasive surgery. The popularization and application of DBS technology is impeded by the duration limit of the battery, regulation of stimulation parameters, selection of optimal target, patient selection criteria and ethical arguments. The exploitation of novel pharmacological agents and targets, more detailed local stimulation devices and extracranial neuromodulation devices within deeper brain structures (which are more effective than transcranial magnetic stimulation) (96), may lead to improvements in DBS technology. The development of other non-invasive effective intracranial targets, including visual purple and halorhodopsin neural circuit photosensitive manipulation, also deserve attention (96).

The aforementioned non-invasive techniques are unable to take the place of DBS. The tracer signal of the DBS electrode combined with a DBS imaging map depicts the evolutionary process of the temporal and spatial brain activities induced by DBS, which provides more information to improve the current research instruments and may lead to increased understanding of the basic pathological mechanisms of brain function (30). DBS is the only neurosurgical treatment method that can be controlled in a blinded study with the advantages of safety, adjustability and reversibility, thus providing a good method for investigating neurobiological mechanisms of mental disease (30).

The scope of DBS to treat mental illnesses may increase with in-depth knowledge of underlying pathological and physiological mechanisms, and the progress of imaging and hardware design technology. It should be emphasized that practitioners of DBS must adopt compulsory ethical standards, as well as exclusion and inclusion criteria, to prevent the practitioners from using this technology beyond the scope of its applications.

For DBS treatment of mental illnesses, optimal target exploration is the most important avenue of research. Current research indicates that there may exist one or more central intracranial targets, including visual purple and halorhodopsin neural circuit photosensitive manipulation, also deserve attention (96). To confirm the final potential central target, non-human primate models should be established according to the definition of refractory mental illness (98). Such a model should be selected based on the ability to imitate every psychotic symptom and pathological process entirely (97). Furthermore, a database should be established compiling the DBS therapeutic targets for every type of mental illness, including the mechanisms, stimulation parameters, curative effects, side effects and postoperative imaging results. Such a database may assist researchers from different institutions in matching suitable patients and treatments, and to rapidly share their study results.

In conclusion, a significant proportion of refractory psychopathic patients may greatly benefit from novel therapeutic methods. DBS treatment is an option that provides the ability to control the pathalogy of neural networks with an accurate and reversible treatment and promising curative effects have been reported. However, considerably more clinical data are required to eliminate basic ethical arguments and a universal standard should be established for patient and target selection. Overall, the application of DBS technology requires creative and adventurous exploration, as well as strict and objective standards.

References


